Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom-Reference-Cited by-同舟云学术

Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Published:2015-09 Issue:6 Volume:18 Page:925-938
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Allen Felicity,Montgomery Stephen^ORCID,Maruszczak Maciej,Kusel Jeanette,Adlard Nicholas

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference47 articles.

1. Multiple sclerosis;Nylander;J Clin Invest,2012

2. Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database;Mackenzie;J Neurol Neurosurg Psychiatry,2014

3. Multiple sclerosis;Compston;Lancet,2002

4. Social participation in patients with multiple sclerosis: correlations between disability and economic burden;Kwiatkowski;BMC Neurol,2014

5. Multiple sclerosis in the UK: service use, costs, quality of life and disability;McCrone;Pharmacoeconomics,2008

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing–Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach;Advances in Therapy;2021-11-18

2. Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis;Value in Health;2021-11

3. How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review;Neurology and Therapy;2021-07-19

4. Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions;PharmacoEconomics;2020-11-26

5. Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies;PharmacoEconomics;2020-09-29